| AZ | EN | RU

STATİSTİKA


ANCA-ASSOSİASİYALI VASKULİTİ OLAN XƏSTƏLƏRDƏ ÜRƏK-DAMAR PATOLOGİYASI
Qasımova F.N., Babayeva L.K., Atakişiyeva V.N., Quliyeva İ.M., Məmmədov M.Y.

DOI: 10.61775/2413-3302.v2i36.02

XÜLASƏ
Məqalədə ANCA assosiasiyalı vaskulit (AAV) olan xəstələrdə ürək-damar patologiyasının xüsusiyyətləri müzakirə olunur, burada onun formalaşma mexanizminə və xəstələrin klinik proqnoza təsirinə xüsusi diqqət yetirilir. Müəllif bu tip vaskuliti olan xəstələrdə ürək-damar xəstəliklərinin tezliyi ilə bağlı məlumatları təhlil edir və damarların iltihabı və xroniki iltihab prosesinin aterosklerozun sürətlənmiş inkişafına kömək edə biləcəyini və bu xəstələrdə ürək-damar ağırlaşmalarının riskini artıra biləcəyini vurğulayır. Məqalədə AAV olan xəstələrin müalicəsi zamanı ürək-damar risk faktorlarının nəzərə alınmasının vacibliyi, bu xəstələrin həyat keyfiyyətini yaxşılaşdırmaq, xəstəliyin nəticələrini proqnozlaşdırmaq üçün onların diaqnostikası və müalicəsində kompleks yanaşmanın zəruriliyi qeyd olunur.
Açar sözlər: ANCA assosiasiyalı vaskulit, damar iltihabı, ürəyin zədələnməsi, ağırlaşmalar

ƏDƏBİYYAT
  1. Almaani S., Fussner L.A., Brodsky S. et al. ANCA-Associated Vasculitis: An Update // J Clin Med., 2021;10 (7):1446. doi: 10.3390/jcm10071446.
  2. Kronbichler A., Leierer J., Gauckler P., Shin J.I. Comorbidities in ANCA-associated vasculitis // Rheumatology (Oxford). 2020;59(Suppl 3): i79-i3. doi:10. 1093/rheumatology/kez617.
  3. Mercuzot C., Letertre S., Daien C.I. et al. Comorbidities and health-related quality of life in patients with Antineutrophil Cytoplasmic Antibody (ANCA) – associated vasculitis // Autoimmun Rev., 2021; 20(1):102708. doi: 10.1016/j.autrev.2020. 102708.
  4. Söderberg D, Segelmark M. Neutrophil extracellular traps in ANCA-associated vasculitis Front // Immunol., 7 (2016), p. 256, doi: 10.3389/fimmu.2016.00256.
  5. Floyd L., Morris A.D., Woywodt A., Dhaygude A. Cardiovascular disease and ANCA-associated vasculitis: are we missing a beat? // Clin Kidney J., 2022;15(4):618-623. doi:10.1093/ckj/sfac009.
  6. Wallace Z.S., Fu X., Harkness T., Stone J.H. et al. All-cause and cause-specific mortality in ANCA-associated vasculitis: overall and according to ANCA type // Rheumatology, 59 (9) (2020), pp. 2308-2315. doi:10.1093/rheumatology/kez589.
  7. Massicotte-Azarniouch D., Petrcich W., Walsh M. et al. Association of anti-neutrophil cytoplasmic antibody-associated vasculitis and cardiovascular events: a population-based cohort study // Clin Kidney J, 15 (4) (2021), pp. 681-692. doi: 10.1093/ckj/sfab229.
  8. Kitching A.R., Anders H.J., Basu N. et al. ANCA‐associated vasculitis // Nat Rev Dis Prim [Internet]. 2020;6(1):71. doi: 10.1038/s41572-020-0204-y.
  9. Goyal A., Qayyum Abbasi H., Mashkoor Y. et al. Assessment of cardiovascular risk in patients with ANCA-associated vasculitis: A systematic review and meta-analysis // International Journal of Cardiology Cardiovascular Risk and Prevention, 2024, Vol. 23, 200334. doi: 10.1016/j.ijcrp.2024.200334.
  10. Borowiec A., Dąbrowski R. Kowalik I. et al. Elevated levels of D-dimer are associated with inflammation and disease activity rather than risk of venous thromboembolism in patients with granulomatosis with polyangiitis in long term observation // Adv. Med. Sci., 2020; 65 (1) pp. 97-101. doi: 10.1016/j.advms.2019. 12.007.
  11. Sun G, Yafasova A, Baslund B, et al. Long-term risk of heart failure and other adverse cardiovascular outcomes in granulomatosis with polyangiitis: A Nationwide Cohort study // J Rheumatol. 2022;49(3):291-298. doi:10.3899/ jrheum.210677.
  12. Guillevin L., Cohen P., Gayraud M. et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients // Medicine, 1999;78:26-37.
  13. Guillevin L., Durand-Gasselin B., Cevallos R. et al. Microscopic polyangitis: clinical and laboratory findings in eighty-five patients // Arthritis Rheum., 1999; 42:421-30.
  14. Reinhold-Keller E., Buege N, Latza U. et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis // Arthritis Rheum., 2000; 43:1021-32.
  15. Hazebroek M.R., Kemna M.J., Schalla S. et al. Prevalence and prognostic relevance of cardiac involvement in ANCA-associated vasculitis: eosinophilic granulomatosis with polyangitis and granulomatosis with polyangiitis // Int J Cardiol., 2015; 199:170-179.
  16. Guillevin L., Lhote F., Gayraud M. et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients // Medicine, 1996; 75:17-28, 15.
  17. Malgorzata Potentas-Policewicz, Justyna Fijolek Granulomatosis with polyangiitis: clinical characteristics and updates in diagnosis // Front. Med., 2024; Sec. Pulm. Medicine, 2024; Vol. 11: 1369233. doi:10.3389/ fmed.2024. 1369233.
  18. Miszalski-Jamka T, Szczeklik W, Sokolowska B. et al. Cardiac involvement in Wegener’s granulomatosis resistant to induction therapy // Eur Radiol., 2011;21: 2297–304. doi: 10.1007/s00330-011-2203-6.
  19. Morelli S., Gurgo Di Castelmenardo A.M, Conti F., Sgreccia A. et al. Cardiac involvement in patients with Wegener’s granulomatosis // Rheumatol Int., 2000;19: 209–12. doi: 10.1007/s002960000059.
  20. Oliveira G.H., Seward J.B, Tsang T.S, Specks U. Echocardiographic findings in patients with Wegener granulomatosis // Mayo Clin Proc., 2005; 80:1435–40. doi: 10.4065/80.11.1435.
  21. McGeoch L., Carette S. Cuthbertson D, et al. Cardiac involvement in granulomatosis with polyangiitis // J Rheumatol., 2015;42(7):1209‐1212. doi: 10.3899/jrheum.141513.
  22. Florian A, Slavich M, Blockmans D, Dymarkowski S, Bogaert J. Cardiac involvement in granulomatosis with polyangiitis (Wegener granulomatosis) // Circulation, 2011;124: e342–4.
  23. Miłkowska-Dymanowska J., LaskowskaP., Rzuczkowski M. et al. Untypical Manifestations of Granulomatosis with Polyangiitis - A Review of the Literature // SN Comprehensive Clinical Medicine, 2019; 1:616–626. doi:10.1007/s42399-019-00083-4.
  24. Marques N, Mimoso J, Bohorquez R, Lázaro M, Brito H, Pereira MA, Valente I, Mendonça I, Gomes V. Unstable angina as initial manifestation of Wegener granulomatosis: case report // Rev Port Cardiol. 2008 Nov;27(11):1469-77. English, Portuguese. PMID: 19227813.
  25. Lazarus M.N, Khurana R, Sethi AS, Naughton MA. Wegener’s granulomatosis presenting with an acute ST-elevation myocardial infarct (STEMI) // Rheumatology, 2006; 45:916–8.
  26. Miloslavsky E., Unizony S. The heart in vasculitis // Rheum Dis Clin North Am, 2014; 40: 11–26. doi: 10.1016/j.rdc.2013.10.006.
  27. Silveira L.H. Cardiovascular manifestations of systemic vasculitides // Curr Rheumatol Rep., 2020; 22(10):72. doi: 10.1007/s11926-020-00952-1.
  28. Байрашевская А.В., Дегтярева Н.Д., Раденска-Лоповок С.Г. АНЦА-ассоциированные васкулиты // Архив патологи, 2022;84(1):50–58. doi: 10.17116/patol20228401150.
  29. Martinez F., Chung J.H, Digumarthy S.R, Kanne J.P, et al. Common and uncommon manifestations of Wegener granulomatosis at chest CT: radiologic-pathologic correlation // Radio Graphics, 2011; 32:51–69.
  30. Cocco G, Gasparyan AY. Myocardial ischemia in Wegener’s granulomatosis: coronary atherosclerosis versus vasculitis // Open Cardiov. Med J. 2010; 4:57–62.
  31. Lim H.E, Lee Y.H, Ahn J.C. Wegener's granulomatosis with progressive conduction disturbances and atrial fibrillation // Heart, 2007;93:777. doi: 10.1136/ hrt.2006.090530.
  32. Goodfield N.E, Bhandari S., Plant W.D. et al. Cardiac involvement in Wegener’s granulomatosis // Br Heart J. 1995; 73:110–5.
  33. Valente F., Rozen L., Carlier S., Godart P. An uncommon case of complete AV block // BMC Cardiov. Disord., 2022;22:429. doi: 10.1186/s12872-022-02866-5.
  34. Emmi G., Bettiol A., Gelain E. et al. Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis // Nat Rev Rheumatol., 2023;19: 378–393. doi:10.1038/s41584-023-00958-w
  35. Furuta S., Iwamoto T., Nakajima H. Update on eosinophilic granulomatosis with polyangiitis // Allergol. Int., 2019;68(4):430-436. doi: 10.1016/j.alit.2019.06.004.
  36. Bond M., Fagni F., Moretti M. et al. At the heart of eosinophilic granulomatosis with polyangiitis: into cardiac and vascular involvement // Curr Rheumatol Rep., 2022;24(11):337‐351. doi: 10.1007/s11926-022-01087-1.
  37. Alexandra Villa-Forte, Brian F. Mandell Cardiovascular Disorders and Rheumatic Disease // Revista Española de Cardiología, 2011; Vol. 64, Issue 9, p. 809-817. doi: 10.1016/j.rec.2011.05.013
  38. Anaev E.Kh., Belevskiy A.S., Kniajeskaia N.P. Eosinophilic granulomatosis with polyangiitis: etiopathogenesis, classification and clinical phenotypes // Pulmonologiya, 2023; 33(3): 393–400. DOI: 10.18093/0869-0189-2022-4101.
  39. Knockaert D.C. Cardiac involvement in systemic inflammatory diseases // Eur. Heart J. 2007; 28 (15): 1797–1804. DOI: 10.1093/ eurheartj/ehm193.
  40. Sinico R.A., Di Toma L., Maggiore U. et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome // Arthritis Rheum., 2005;52:2926-35. doi: 10.1002/art. 21250.
  41. Mavrogeni S., Karabela G., Gialafos E. et al. Cardiac involvement in ANCA (+) and ANCA (-) Churg-Strauss syndrome evaluated by cardiovascular magnetic resonance // Inflamm. Allergy Drug Targets, 2013; 12(5):322-327. doi: 10.2174/ 18715281113129990054.
  42. Sinico R.A., Di Toma L., Maggiore U. et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome // Arthritis Rheum., 2005;52:2926-35. doi: 10.1002/art. 21250.
  43. Mavrogeni S., Karabela G., Gialafos E. et al. Cardiac involvement in ANCA (+) and ANCA (-) Churg-Strauss syndrome evaluated by cardiovascular magnetic resonance // Inflamm. Allergy Drug Targets, 2013; 12(5):322-327. doi: 10.2174/ 18715281113129990054.
  44. Ribi C., Cohen P., Pagnoux C. et al. Treatment of Churg-Strauss syndrome without poor- prognosis factors: multicenter, prospective, randomized, open-label study of seventy-two patients // Arthritis Rheum., 2008;58(2):586-94. doi: 10.1002/art.23198.
  45. Bourgarit A., Le Toumelin P., Pagnoux C. et al. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients // Medicine, 2005; 84(5):323-30. doi: 10.1097/01. md.0000180793.80212.17.
  46. Терапия по Сесилю: в 4 т. Т. ІІІ / под ред. Л. Голдмана, Э. Шафера - Москва: ГЭОТАР-Медиа, 2023; 1184. с. doi: 10.33029/978-5-9704-7003-9-GCM-2023-1-1184.
  47. Ahn J. K. Clinical features and outcome of microscopic polyangiitis under a new consensus algorithm of ANCA-associated vasculitis in Korea / J. K. Ahn [et al.] // Rheumatology international, 2011; Vol. 32, №10: Р. 2979–2986.
  48. Mavrogeni S., Manoussakis M.N., Karagiorga T.C. Detection of coronary artery lesions and myocardial necrosis by magnetic resonance in systemic necrotizing vasculitides //Arthritis Rheum., 2009 Aug 15;61(8):1121-9. doi: 10.1002/art.24695.
  49. Katarzyna Życińska, Anna Borowiec Cardiac manifestations in antineutrophil cytoplasmic autoantibody (ANCA) — associated vasculitides // Kardiologia Polska, 2016; 74, 12: 1470–1476; DOI: 10.5603/KP.a2016.0138.